INT241797
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
During ERT, clinical abnormality rates decreased (except for neurological involvement) and the biological data improved overall during ERT (increased hemoglobin, leukocyte and platelet levels; decreased chitotriosidase, ACE, TRAP, ferritin and gammaglobulin levels). | |||||||||||||||
| |||||||||||||||
|
Choi et al. have shown in a study in South India that patients are more susceptible to W. bancrofti infection if they are homozygous for the allele that is responsible for lower levels of chitotriosidase (CHIT1), a protein found in phagocytic cells (73). | |||||||||||||||
| |||||||||||||||
|
Choi et al. have shown in a study in South India that patients are more susceptible to W. bancrofti infection if they are homozygous for the allele that is responsible for lower levels of chitotriosidase (CHIT1), a protein found in phagocytic cells (73). | |||||||||||||||
| |||||||||||||||
|
After a total of 12 months treatment, spleen and liver volumes, and chitotriosidase levels decreased by only 10%, 6%, and 15%, respectively (Table 1). | |||||||||||||||
| |||||||||||||||
|
It is essential to monitor the disease progression by checking levels of hemoglobin, platelets, chitotriosidase every 36 months and liver and spleen volumes and bone studies including dual energy X-ray absorptiometry (DXA) scan and bone MRI once a year. | |||||||||||||||
| |||||||||||||||
|
While chitotriosidase is one of the established biomarkers for GD, it has been recently used as an indicator in alveolar lung diseases, such as sarcoidosis and miliary tuberculosis.93,94 Chitotriosidase levels are shown to be significantly higher in patients with idiopathic interstitial lung disease.95 | |||||||||||||||
| |||||||||||||||
|
Unlike recombinant enzymes, SRT agents are small molecules that can cross the blood-brain barrier.59 Although improved pulmonary function, and a significant decrease in chitotriosidase levels have been observed in patients with GD type 3, miglustat unfortunately, does not appear to have any significant benefits on the neurological manifestations of GD.60 | |||||||||||||||
| |||||||||||||||
|
During ERT, clinical abnormality rates decreased (except for neurological involvement) and the biological data improved overall during ERT (increased hemoglobin, leukocyte and platelet levels; decreased chitotriosidase, ACE, TRAP, ferritin and gammaglobulin levels). | |||||||||||||||
| |||||||||||||||
|
While chitotriosidase is one of the established biomarkers for GD, it has been recently used as an indicator in alveolar lung diseases, such as sarcoidosis and miliary tuberculosis.93,94 Chitotriosidase levels are shown to be significantly higher in patients with idiopathic interstitial lung disease.95 | |||||||||||||||
| |||||||||||||||
|
After a total of 12 months treatment, spleen and liver volumes, and chitotriosidase levels decreased by only 10%, 6%, and 15%, respectively (Table 1). | |||||||||||||||
| |||||||||||||||
|
It is essential to monitor the disease progression by checking levels of hemoglobin, platelets, chitotriosidase every 36 months and liver and spleen volumes and bone studies including dual energy X-ray absorptiometry (DXA) scan and bone MRI once a year. | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.